Suppression of E-protein activity interferes with the development of BCR-ABL-mediated myeloproliferative disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 35, 2008, Pages 12967-12972

  Ko, Jinkyung ^a   Patel, Nihal ^b   Ikawa, Tomokatsu ^c   Kawamoto, Hiroshi ^c   Frank, Oliver ^d   Rivera, Richard R ^a   Van Etten, Richard A ^a   Murre, Cornelis ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c RIKEN Center for Integrative Medical Sciences   (Japan)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chronic myeloid leukemia; Id2; Myeloproliferative disorder

Indexed keywords

BCR ABL PROTEIN; E PROTEIN; HELIX LOOP HELIX PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MATURATION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COLONY FORMING UNIT GM; DNA BINDING; FEMALE; GRANULOCYTOSIS; HEPATOMEGALY; LEUKOCYTOSIS; LIVER; LUNG; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; MOUSE STRAIN; MYELOPROLIFERATIVE DISORDER; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; SPLEEN; SPLENOMEGALY;

3T3 CELLS; ANIMALS; BONE MARROW; FUSION PROTEINS, BCR-ABL; INHIBITOR OF DIFFERENTIATION PROTEIN 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED C57BL; MYELOPROLIFERATIVE DISORDERS; NEUTROPHILS;

MURINAE; MUS;

EID: 51349158875     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0805073105     Document Type: Article

References (41)

1. van Etten RA, Shannon KM (2004) JAKing up hematopoietic proliferation. Cancer Cell 6:547-552.
2. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, et al. (1999) The biology of chronic myelogenous leukemia. N Eng J Med 341:164-172.
3. van Etten RA (2007) Aberrant cytokine signaling in leukemia. Oncogene 26:6738-6749.
4. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, et al. (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 300:765-767.
5. Daley GQ, van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824-830.
6. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr/Abl positive cells. Nat Med 2:561-566.
7. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, et al. (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102:276-283.
8. Murre C (2005) Helix-loop-helix proteins in lymphocyte development. Nat Immunol 6:1079-1086.
9. Massari ME, Murre C (2000) Helix-loop-helix proteins: Regulators of transcription in eukaryotic organisms. Mol Cell Biol 20:429-40.
10. Bain G, Cravatt, C. Loomans C, Alberola-Ila J, Hedrick SM, et al. (2001) Regulation of the helix-loop-helix proteins, E2A and Id3, by the Ras-ERK MAPK cascade. Nat Immunol 2:165-171.
11. Bain G, Maandag EC, Izon DJ, Armsen D, Kruisbeek AM, et al. (1994). E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell 79:885-892.
12. Zhuang Y, Soriano P, Weintraub H (1994). The helix-loop-helix gene E2A is required for B cell formation. Cell 79:875-884.
13. Heemskerk MH, Blom B, Nolan G, Stegmann AP, Bakker AQ, et al. (1997) Inhibition of T cell and promotion of natural killer cell development by the dominant negative factor ID3. J Exp Med 186:1597-1602.
14. Engel I, Johns C, Bain G, Rivera RR, Murre C (2001) Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. J Exp Med 194:733-745.
15. Barndt RJ, Dai M, Zhuang Y (2000) Functions of E2A-HEB heterodimers in T-cell development revealed by a dominant negative mutation of HEB. Mol Cell Biol 20:6677-6685.
16. Ikawa T, Kawamoto H, Goldrath AW, Murre C (2006) E-proteins and Notch signaling cooperate to promote T cell lineage specification and commitment. J Exp Med 203:1329-1342.
17. Boos MD, Yokota, Y. Eberl G, Kee BL (2007) Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2-mediated suppression of E protein activity. J Exp Med 204:1119-1130.
18. Benezra R, Davis RL, Lassar A, Tapscott S, Thayer M, et al. (1990) Id: A negative regulator of helix-loop-helix DNA binding proteins. Control of terminal myogenic differentiation. Cell 61:49-59.
19. Rivera RR, Johns CP, Quan J, Johnson RS, Murre C (2000) Thymocyte selection is regulated by the helix-loop-helix inhibitor protein, Id3. Immunity 12:17-26.
20. Yan W, Young AZ, Soares VC, Kelley R, Benezra R. et al. (1997). High incidence of T-cell tumors in E2A-null mice and E2A/Id1 double-knockout mice. Mol Cell Biol 17:7317-7327.
21. Buitenhuis M, van Deutekom HW, Verhagen LP, Castor A, Jacobsen SW, et al. (2005). Differential regulation of granulopoiesis by the basic helix-loop-helix transcriptional inhibitors Id1 and Id2. Blood 105:4272-4281.
22. Yokota Y, Mansouri A, Mori S, Sugawara S, Adachi S, et al. (1999). Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 397:702-706.
23. Hacker C, Kirsch RD, Ju XS, Hieronymus T, Gust TC, et al. (2003) Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol 4:380-386.
24. Cannarile MA, Lind NA, Rivera R, Sheridan AD, Camfield KA, et al. (2006) Transcriptional regulator Id2 mediates CD8+ T cell immunity. Nat Immunol 7:1317-1325.
25. Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, et al. (2003) Chronic myelogenous leukemia molecular signature. Oncogene 22:3952-3963.
26. Look AT (1997) E2A-HLF chimeric transcription factors in pro-B cell acute lymphoblastic leukemia. Curr Top Microbiol Immunol 220:45-53.
27. Kamps MP, Murre C, Sun X, Baltimore D (1990) A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. Cell 60:547-555.
28. Nourse J, Mellentin JD, Galili N, Wilkinson J, Stanbridge E, et al. (1990) Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor. Cell 60:535-545.
29. Bain G, Engel I, Robanus Maandag EC, te Riele HPJ, Voland JR, et al. (1997) E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas. Mol Cell Biol 17:4782-4791.
30. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M (2004) TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 5:587-596.
31. Ferrando AA, Look AT (2003) Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol 40:274-280.
32. Morrow MA, Mayer EW, Perez CA, Adlam M, Siu G (1999) Overexpression of the Helix-Loop-Helix protein Id2 blocks T cell development at multiple stages. Mol Immunol 36:491-503.
33. Engel I, Murre C (1999). Ectopic expression of E47 or E12 promotes the death of E2A-deficient lymphomas. Proc Natl Acad Sci USA, 96:996-1001.
34. Engel I, Murre C (2004) E2A proteins enforce a proliferation checkpoint in developing thymocytes. EMBO J 23:202-211.
35. Zhao F, Vilardi A, Neely RJ, Choi JK (2001) Promotion of cell cycle progression by basic helix-loop-helix E2A. Mol Cell Biol 21:6346-6357.
36. Peverali FA, Ramqvist T, Saffrich R, Pepperkok R, Barone MV, et al. (1994) Regulation of G1 progression by E2A and Id helix-loop-helix proteins. EMBO J 13:4291-4301.
37. Schwartz R, Engel I, Fallahi-Sichani, Petrie HT, Murre C (2006) Gene expression patterns define novel roles for E47 in cell cycle progression, cytokine-mediated signaling, and T lineage development. Proc Natl Acad Sci USA 103:9976-9981.
38. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, et al. (1998) Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92:3780-3792.
39. Million RP, Aster J, Gilliland DG, van Etten RA (2002) The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. Blood 99:4568-4577.
40. Li S, Ilaria RL, Million RP, Daley GQ, van Etten RA (1999) The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 189:1399-1412.
41. Roumiantsev S, de Aos IE, Varticovski L, Ilaria RL, van Etten RA (2001) The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood 97:4-13.